EU DMF readiness
💉 Available also
in injectable form
Piracetam is an antimyoclonic agent.
Piracetam is indicated in adult patients suffering from myoclonus of cortical origin, irrespective of etiology, and should be used in combination with other anti-myoclonic therapies.
It is formulated solution, syrup, film coated tablets for oral route of administration and injection, solution for intravenous route of administration.
Mechanism of action:
Piracetam is a positive allosteric modulator of the AMPA receptor.
It acts on ion channels or ion carriers leading to increased neuron excitability and has been found to increase blood flow glucose and oxygen consumption in parts of the brain which precedes cognitive improvement. Piracetam improves the function of the neurotransmitter acetylcholine via muscarinic cholinergic (ACh) receptors, which are implicated in memory processes. Furthermore, piracetam may have an effect on NMDA glutamate receptors, which are involved in learning and memory processes.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).
The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.